About this trial
Ventricular repolarization, measured by corrected QT interval (QTc), is influenced by sex hormones. A QTc above 460msec predisposes to the risk of "torsades-de-pointes"(TdP). The investigators have recently shown that estradiol determines an increase in QTc elongation and progesterone shortens it. In addition, high gonadotropin levels (FSH or LH) are associated with QTc prolongation. Hypergonadotropic hypogonadisms (low progesterone and high gonadotropins) are therefore hormonal situations that promote QTc prolongation. Premature ovarian insufficiency (POI) is one of them. Its management is based on the prescription of hormone replacement therapy (HRT). Epidemiological studies have shown that these patients would be at increased risk of cardiovascular mortality. Our team is interested in the effect of this pathological hormonal situation and its HRT on ventricular repolarization in order to define whether this is a population at risk for long QTc.
Eligibility criteria
Qualifiers
Patient aged 18 to 41 years
Patient with POI diagnostic criteria (FSH >25UI/l twice at intervals of a few weeks) with amenorrhea
No hormone treatment interacting with the gonadotropic axis for at least one month before inclusion
Patient who has signed informed consent
Disqualifiers
Patient on HRT during the 1st evaluation
Pregnant or breastfeeding woman
Treatment regimen known to lengthen QT or act on ventricular repolarization
Cardiac history in particular cardiac rhythm disorder
Trial design
Treatments tested in this trial
- Hormone replacement therapy:effect on ventricular repolarization
- ECG